



Precision BioSciences to Participate in Upcoming Stifel Genetic Medicines Day

May 24, 2023

DURHAM, N.C.--(BUSINESS WIRE)--May 24, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based *in vivo* gene editing and *ex vivo* allogeneic CAR T therapies, today announced that the Company will participate in the Stifel Genetic Medicines Day taking place May 30, 2023.

Details for the virtual fireside chat are as follows:

Date: Tuesday, May 30, 2023

Time: 2:25 PM ET

The fireside chat will be available via a live webcast accessible on Precision's website in the Investors section under Events & Presentations on May 30, 2023: <https://investor.precisionbiosciences.com/events-and-presentations>. An archived replay will be available for approximately 30 days following the event.

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company's pipeline consists of several *in vivo* gene editing candidates designed to cure genetic and infectious diseases where no adequate treatments exist and multiple *ex vivo* clinical candidates. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.

View source version on [businesswire.com](https://www.businesswire.com): <https://www.businesswire.com/news/home/20230524005508/en/>

Investor and Media Contact:

Mei Burris

Director, Investor Relations & Finance

Mei.burris@precisionbiosciences.com

Source: Precision BioSciences, Inc.